Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziftomenib + venetoclax + gemtuzumab ozogamicin
- Development stage
- Unknown
- Lead developer
- Kura Oncology
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
This combination therapy consists of ziftomenib, venetoclax, and gemtuzumab ozogamicin. Ziftomenib is a potent, oral small molecule inhibitor of the menin-KMT2A (MLL) interaction, which is critical for the survival of leukemias with specific genetic alterations like KMT2A rearrangements or NPM1 mutations. Venetoclax is a selective BCL-2 inhibitor that induces apoptosis in leukemia cells. Gemtuzumab ozogamicin is a CD33-directed antibody-drug conjugate that delivers a cytotoxic calicheamicin derivative to myeloid cells. This triplet regimen is being evaluated by M.D. Anderson Cancer Center in a Phase 1 trial for pediatric patients with relapsed or refractory acute myeloid leukemia (AML) or mixed phenotype acute leukemia (MPAL), particularly those harboring KMT2Ar, NUP98r, NPM1c, or UBTF-ITD mutations.
- Brand names
- KomziftiVenclextaMylotarg
- Other names
- Ziftomenib + Venetoclax + Gemtuzumab ozogamicin
02
Targets
CD33 (Myeloid cell surface antigen CD33)BCL-2 (BCL-2 family)MEN1 (Menin)
Beyond the preview
Go deeper on ziftomenib + venetoclax + gemtuzumab ozogamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziftomenib + venetoclax + gemtuzumab ozogamicin.